U.S. Markets close in 1 hr 35 mins

AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane

Daniel Collins
AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane

In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter. In US and international markets, Duodopa saw revenue of $17 million and $77 million, respectively, reflecting ~55.2% and ~23% growth YoY.